Higher systolic blood pressure is associated with progression of carotid intima–media thickness in patients with chronic kidney disease  by Kendrick, Jessica et al.
see commentary on page 753
Higher systolic blood pressure is associated with
progression of carotid intima–media thickness in
patients with chronic kidney disease
Jessica Kendrick1, Michel Chonchol1, Hannes Gnahn2 and Dirk Sander3,4
1Division of Renal Diseases and Hypertension, University of Colorado Denver Health Sciences Center, Aurora, Colorado, USA; 2INVADE
Study Group, Ebersberg, Germany; 3Department of Neurology, Technical University of Munich, Munich, Germany and 4Medical Park
Hospital, Bischofswiesen, Germany
To examine the relationship between systolic blood pressure
and progression of carotid intima–media thickness in patients
with chronic kidney disease (CKD), we studied 3364 patients
from a community-based cohort of elderly individuals of
whom 724 had CKD defined as creatinine clearances of stage
3 or less. The contribution of systolic blood pressure was
evaluated in four ranges (o120, 120–129, 130–139, and
X140mmHg). All multiple linear regression analyses were
adjusted for traditional and nontraditional cardiovascular risk
factors. The higher ranges of systolic blood pressure at
baseline were associated with a greater carotid intima–media
thickness at the initiation of the study in patients with or
without CKD. Covariate-adjusted averages of carotid
intima–media thickness at the initiation of the study in
patients with CKD significantly increased across the four
strata of systolic blood pressure. Higher systolic blood
pressure at baseline was associated with a significantly
greater yearly change in covariate-adjusted mean carotid
intima–media thickness and vascular events in patients with
CKD over a 4-year follow-up period.
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Chronic kidney disease (CKD) is a worldwide health problem
affecting 13% of the US adult population.1 CKD may reach
epidemic proportions over the next decade with the aging
of the population, as well as the increased incidence of
hypertension and diabetes.1,2 The morbidity and mortality
associated with CKD is substantial and a large proportion is
attributed to cardiovascular disease (CVD), as patients with
CKD have a high prevalence of both traditional and
nontraditional cardiovascular risk factors.3
Hypertension is a major risk factor for CVD, including
coronary events, congestive heart failure, and stroke.4–6 It is well
established that blood pressure lowering has been shown to
reduce CVD morbidity and mortality in the general popula-
tion.7–9 Hypertension is also highly prevalent in CKD,10,11 and
the target blood pressure has been progressively lowered in this
population.12 However, the effect of blood pressure lowering
on cardiovascular outcomes in patients with moderate CKD
has not yet been examined in randomized controlled trials, and
few observational studies have evaluated the systolic blood
pressure (SBP) level that affects the risk for cardiovascular
events in subjects with CKD not requiring dialysis.13,14
Carotid intima–media thickness (IMT) is a useful, non-
invasive evaluation of early carotid atherosclerosis and is
independently related to the risk of cardiovascular events.15
In individuals with CKD, carotid IMT is associated with all-
cause mortality, CVD, and kidney disease progression, and
therefore may help risk stratify this high-risk population.16–20
However, the relationship between SBP, carotid IMT
progression, and cardiovascular outcomes in CKD subjects
has not been examined extensively.
The purpose of this analysis is to evaluate the relationship
between SBP, carotid IMT progression, and CVD outcomes
in participants with and without CKD in the INVADE
(Intervention Project on Cerebrovascular Diseases and
Dementia in the Community of Ebersberg, Bavaria) study.21
RESULTS
Baseline characteristics
Of the 3364 participants included in the analysis, 724
(21.5%) had CKD at baseline defined as a creatinine
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clearance (Ccr)o60 ml/min per 1.73 m2 (Table 1). The mean
Ccr (±s.d.) in the CKD and non-CKD groups was (50±9)
and (83±18) ml/min per 1.73 m2, respectively. Participants
with CKD were significantly older, had a higher prevalence of
ischemic heart disease, stroke, hypertension, diabetes, and
usage of antihypertensive medications than did those without
CKD. Subjects with CKD also had higher SBP at baseline
than did those without CKD (SBP 139±18 vs 137±
18 mm Hg, P¼ 0.016). Carotid IMT was also higher at
baseline in participants with CKD (0.78±0.18 vs 0.84±
0.21 mm, Po0.001). It is noteworthy that patients with the
lowest Ccr were more likely than were those with higher
levels of kidney function to have higher levels of hs-C-
reactive protein (CRP) and homocysteine.
Baseline carotid IMT according to SBP and kidney function at
the initiation of the study
Carotid IMT in relation to SBP in participants with and
without CKD at baseline is shown in Figure 1. At the
initiation of the study, a higher baseline SBP group was
significantly associated with a higher carotid IMT measure-
ment, irrespective of CKD status in age-adjusted analysis
(F¼ 11.8, Po0.0001 for participants with a CcrX60 and
F¼ 14.5, Po0.0001 for participants with a Ccro60 ml/min
per 1.73 m2). After adjustment for demographics, body mass
index, smoking, prevalent ischemic heart disease, stroke,
baseline diastolic blood pressure, antihypertensive medica-
tions, statin administration, aspirin usage, low-density
lipoprotein-cholesterol, high-density lipoprotein-cholesterol,
triglycerides, glycosylated hemoglobin (HbA1c), hs-CRP, and
homocysteine, the covariate-adjusted mean (95% confidence
interval (95% CI)) of carotid IMT increased with higher SBP
groups, from 0.81 mm (95% CI: 0.74; 0.88) among CKD
subjects with a SBPo120 mm Hg to 0.87 mm (95% CI: 0.70;
1.04) in those CKD participants with a SBPX140 mm Hg
(F¼ 6.1, P¼ 0.01; Figure 1). A similar linear relationship
between higher baseline SBP and increased carotid IMT
was observed in non-CKD participants (F¼ 3.3, P¼ 0.02;
Figure 1). Therefore, CKD subjects with a baseline
SBPX140 mm Hg had the highest baseline carotid IMT. In
addition, the model was repeated evaluating SBP as a
continuous variable; after multivariate adjustment, carotid
IMT increased by 0.017 mm (95% CI: 0.013; 0.022;
P¼ 0.0001) and 0.020 mm (95% CI: 0.008; 0.030;
P¼ 0.0001) per 10 mm Hg increase of SBP in participants
with normal kidney function and CKD, respectively. There
was a significant interaction between SBP and kidney
function status (P¼ 0.009).
In addition to evaluating the relationship between SBP
and carotid IMT at baseline, we also examined the relation-
ship between pulse pressure and carotid IMT at the initiation
of the study. As with SBP, baseline carotid IMT increased
with higher baseline pulse pressure in both age-adjusted
Table 1 | Baseline characteristics in participants by baseline
kidney function (n=3364)
Characteristic
CcrX60ml/min
per 1.73m2
(83±18)
(n=2640)
Ccro60ml/min
per 1.73m2
(50±9)
(n=724) P-value
Age (years) 65±7 74±8 o0.001
Sex (male, n (%)) 1086 (41.1%) 288 (39.8%) 0.13
Body mass index (kg/m2) 28±5 26±5 o0.001
Pack-years of smoking 8.2±17.7 5.3±13.0 o0.001
Smoking (n (%))
Current 287 (10.9%) 46 (6.4%) 0.003
Former 647 (24.%) 152 (21.0%) 0.009
Never 1706 (64.6%) 526 (72.7%) 0.002
Ischemic heart disease (n (%)) 251 (9.5%) 169 (23.3%) o0.001
Stroke (n (%)) 62 (2.4%) 43 (6.0%) o0.001
Arterial hypertension (n (%)) 1394 (52.8%) 518 (71.6%) o0.001
Diabetes (n (%)) 266 (10.1%) 195 (27.0%) o0.001
Medication use
Antihypertensive
medication (n (%))
1375 (52.1%) 519 (71.7%) o0.001
Lipid-lowering medication
(n (%))
415 (15.7%) 133 (18.4%) 0.05
Measurements
Systolic blood pressure
(mmHg)
137±18 139±18 0.016
Diastolic blood pressure
(mmHg)
83±10 80±10 o0.001
LDL-C (mg/dl) 131±39 129±39 0.37
HDL-C (mg/dl) 58.3±16.5 58.1±16.1 0.81
Triglyceride (mg/dl) 144±85 143±75 0.85
HbA1c (%) 5.7±0.86 5.9±0.88 0.003
Baseline creatinine (mg/dl) 0.82±0.16 1.16±0.50 o0.001
hs-CRP (mg/l) 3.9±2.6 4.4±3.7 0.022
Homocysteine (mg/l) 6.6±3.6 8.9±4.4 o0.001
Baseline carotid IMT (mm) 0.78±0.18 0.84±0.21 o0.001
Abbreviations: Ccr, creatinine clearance; HbA1c, glycosylated hemoglobin; HDL-C,
high-density lipoprotein-cholesterol; hsCRP, high sensitivity C-reactive protein; IMT,
intima–media thickness; LDL-C, low-density lipoprotein-cholesterol.
All values expressed as means±s.d. or number (percentage of participants).
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Figure 1 |Carotid intima–media thickness according to systolic
blood pressure and kidney function at initiation of the study.
The covariate-adjusted means (95% CI) for carotid intima–media
thickness (mm) at baseline are shown. P by ANCOVA for
Ccr X60ml/min¼ 0.02; Ccro60ml/min¼ 0.01. Adjusted for age,
sex, body mass index, smoking, prevalent ischemic heart disease,
stroke, baseline diastolic blood pressure, antihypertensive
medications, statin administration, aspirin usage, low-density-
lipoprotein cholesterol, high-density-lipoprotein cholesterol,
triglycerides, glycosylated hemoglobin, C-reactive protein, and
homocysteine. ANCOVA, analysis of covariance; Ccr, creatinine
clearance; CI, confidence interval; IMT, intima–media thickness.
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(F¼ 8.8, P¼ 0.002 for participants with a CcrX60 and
F¼ 11.4, Po0.0001 for participants with a Ccro60 ml/min
per 1.73 m2) and multivariate analyses, irrespective of CKD
status (F¼ 3.7, P¼ 0.01 for participants with a CcrX60 and
F¼ 6.7, P¼ 0.01 for participants with a Ccro60 ml/min per
1.73 m2; Figure 2). Again, there was a significant interaction
between pulse pressure and CKD status (P¼ 0.02), and the
highest carotid IMT was observed in patients with a baseline
pulse pressure 466 mm Hg and CKD.
Carotid IMT progression according to SBP and kidney
function at baseline
The relationship between CKD status and SBP at baseline
with carotid IMT progression after a 4-year follow-up period
is depicted in Figure 3. In age-adjusted (F¼ 9.5, P¼ 0.009 for
participants with a CcrX60 and F¼ 14.1, P¼ 0.0001 for
participants with a Ccro60 ml/min per 1.73 m2) and multi-
variate adjustment, a significant trend for progression of
carotid IMT was observed with increasing baseline levels
of SBP groups in participants with normal kidney function
(F¼ 7.4, P¼ 0.007) and CKD (F¼ 8.5, P¼ 0.01; Figure 3).
After adjustment for both traditional and nontraditional
cardiovascular risk factors, participants with a SBPX
140 mm Hg and CKD had the greatest amount of carotid
IMT progression. The covariate-adjusted means of carotid
IMT progression increased almost threefold in participants
with an elevated SBPX140 mm Hg and CKD, when com-
pared with participants with normal or near normal kidney
function and a SBPo120 mm Hg (Figure 3). The analysis
was repeated using SBP as a continuous variable; after
multivariate adjustment, the covariate-adjusted means of
carotid IMT increased by 0.0015 mm per year (95% CI:
0.0011; 0.0028; P¼ 0.01) and by 0.0022 mm per year (95%
CI: 0.0010; 0.0032; P¼ 0.008) per 10 mm Hg increase of SBP
in participants with normal kidney function and CKD,
respectively. Similarly, in multivariate analyses, increasing
baseline pulse pressure was associated with carotid IMT
progression in participants with (F¼ 8.2, P¼ 0.009) and
without kidney disease (F¼ 6.7, P¼ 0.01; Figure 4). It is
noteworthy that there was a significant interaction between
SBP and kidney function status (P¼ 0.007) and pulse
pressure and CKD status (P¼ 0.01).
Interestingly, in multivariate analyses, which included
systolic and diastolic blood pressure as covariates, usage of
angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers at baseline were significantly associated
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Figure 2 |Carotid intima–media thickness according to pulse
pressure and kidney function at initiation of the study. The
covariate-adjusted means (95% CI) for carotid intima–media
thickness (mm) at baseline are shown. P by ANCOVA for
CcrX60ml/min¼ 0.01; Ccro60ml/min¼ 0.01. Adjusted for age,
sex, body mass index, smoking, prevalent ischemic heart disease,
stroke, baseline systolic and diastolic blood pressures,
antihypertensive medications, statin administration, aspirin usage,
low-density-lipoprotein cholesterol, high-density-lipoprotein
cholesterol, triglycerides, glycosylated hemoglobin, C-reactive
protein, and homocysteine. ANCOVA, analysis of covariance;
Ccr, creatinine clearance; CI, confidence interval; IMT,
intima–media thickness.
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Figure 3 |Carotid intima–media thickness progression
according to systolic blood pressure and kidney function at
baseline. The covariate-adjusted means (95% CI) for carotid
intima–media thickness progression (mm per year) are shown.
P by ANCOVA for CcrX60ml/min¼ 0.007; Ccro60ml/min¼ 0.01.
Adjusted for age, sex, body mass index, smoking, prevalent
ischemic heart disease, stroke, baseline diastolic blood pressure,
antihypertensive medications, statin administration, aspirin usage,
low-density-lipoprotein cholesterol, high-density-lipoprotein
cholesterol, triglycerides, glycosylated hemoglobin, C-reactive
protein, homocysteine, and baseline carotid intima
media–thickness. ANCOVA, analysis of covariance; Ccr, creatinine
clearance; CI, confidence interval; IMT, intima–media thickness.
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Figure 4 |Carotid intima–media thickness progression
according to pulse pressure and kidney function at baseline.
The covariate-adjusted means (95% CI) for carotid intima–media
thickness (mm per year) are shown. P by ANCOVA for CcrX60ml/
min¼ 0.011; Ccro60ml/min¼ 0.009. Adjusted for age, sex, body
mass index, smoking, prevalent ischemic heart disease, stroke,
baseline systolic and diastolic blood pressures, antihypertensive
medications, statin administration, aspirin usage, low-density
lipoprotein-cholesterol, high-density lipoprotein-cholesterol,
triglycerides, glycosylated hemoglobin, C-reactive protein,
homocysteine, and baseline carotid intima–media thickness.
ANCOVA, analysis of covariance; Ccr, creatinine clearance;
CI, confidence interval; IMT, intima–media thickness.
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with a decrease in carotid IMT progression in participants
with CKD (standardized b: 0.124; P¼ 0.01) and without
CKD (standardized b: 0.099; Po0.0001). In contrast,
we did not observe a significant association between statin
use at the initiation of the study and IMT progression in
CKD (P¼ 0.08) and non-CKD participants (P¼ 0.15).
Vascular events according to SBP and kidney function
After 4 years of follow-up, 195 participants experienced a
major cardiovascular event (such as myocardial infarction,
stroke, or vascular death); 145 of 2640 (5.5%) participants
with baseline CcrX60 ml/min per 1.73 m2 and 50 of 724
(7.0%) participants with Ccro60 ml/min per 1.73 m2. In
fully adjusted analyses, participants with and without CKD
had a linear relationship between baseline SBP and incident
cardiovascular events (Table 2). SBP at baseline above the
reference group (120–129 mm Hg) was associated with a
higher risk of cardiovascular events in both the CKD and the
non-CKD groups. There was a trend toward a decreased risk
of CV events with a baseline SBPo120 mm Hg in both the
CKD and the non-CKD groups, but it did not reach
statistical significance (hazard ratio 0.95, 95% CI: 0.91–1.24;
P¼ 0.88 and hazard ratio 0.77, 95% CI: 0.68–1.01; P¼ 0.05,
respectively).
A similar relationship between baseline SBP and pulse
pressure with carotid IMT at baseline or carotid IMT
progression was observed in regression models in which
kidney function was entered as a continuous variable instead
of a categorical variable.
All analyses were again repeated estimating kidney
function using the four-variable MDRD (Modification of
Diet in Renal Disease) equation. Results obtained were
similar when kidney function was estimated using the MDRD
prediction equation rather than Ccr estimated by the
Cockcroft–Gault formula (not shown).
DISCUSSION
This population-based study shows several important find-
ings that may have implications for approaches to blood
pressure and CVD management in CKD patients. First, we
found that higher baseline SBP and pulse pressure are
independently associated with greater carotid IMT progres-
sion regardless of the presence or absence of CKD. Second,
higher baseline SBP predicts vascular events in subjects with
and without CKD after adjusting for both traditional and
nontraditional risk factors, although the magnitude of the
risk seems to be higher in patients with CKD than in those
with normal or near normal kidney function. Finally, partici-
pants with the lowest baseline SBP (that is, SBPo120 mm Hg)
with and without kidney disease had similar magnitude in the
association with vascular events, although it only approached
statistical significance in those subjects with normal kidney
function. Hence, the relationship between SBP and incident
vascular events in both groups appeared to be linear.
Carotid IMT measurement is a very powerful indicator of
the whole atherosclerosis burden within all arterial beds, and
has a predictive value not only for adverse cerebral events but
also for cardiac and peripheral vascular events in the general
population and in patients with CKD.15,18,19,22–24 Further-
more, large cohort studies25–27 that have used multiple
measurements of carotid IMT to investigate determinants of
subclinical atherosclerosis progression have shown that risk
factors such as age, smoking, dyslipidemia, and hypertension
are the main predictors of increased carotid IMT. However,
the association of different blood pressure levels on carotid
IMT progression in subjects with moderate CKD has not
been examined. In our analysis, participants with higher
baseline SBP and pulse pressure, regardless of CKD status,
had a greater burden of carotid IMT at baseline and at the
end of the follow-up period. Subjects with CKD and a
baseline SBPX140 mm Hg had the greatest amount not only
of carotid IMT progression but also of incident cardiovas-
cular events independent of other important traditional and
nontraditional risk factors, including, age, smoking, and
dyslipidemia. Thus, the results of our study suggest that
lower SBP levels at the initiation of the observation period
seem to have a lower rate of carotid IMT progression
independent of kidney function.
Our findings complement recent observations suggesting
that kidney disease is strongly associated with greater carotid
IMT.18 Subjects with autosomal dominant polycystic kidney
disease, even with preserved renal function, have greater
carotid IMT compared with healthy controls, and carotid
IMT is highest in hypertensive autosomal dominant poly-
cystic kidney disease patients.28 In a longitudinal study of 203
Asian subjects with stage III and IV CKD, baseline carotid
IMT was a strong independent predictor of cardiovascular
events.29 The average carotid IMT at baseline of the Asian
Table 2 | Hazard ratios of vascular events according to baseline systolic blood pressure group in participants with and without
chronic kidney disease
Parameter
Ccr460ml/min per 1.73m2
HR (95% CI)a P-value
Ccrp60ml/min per 1.73m2
HR (95% CI)a P-value
SBPo120mmHg 0.77 (0.68, 1.01) 0.05 0.95 (0.91,1.24) 0.88
SBP 120–129mmHg (reference) 1.0 — 1.0 —
SBP 130–139mmHg 1.13 (1.05, 1.45) 0.03 1.41 (1.21, 2.01) 0.02
SBPX140mmHg 1.26 (1.15, 1.99) 0.009 1.71 (1.5, 2.3) 0.006
Abbreviations: Ccr, creatinine clearance; CI, confridence interval; HR, hazard ratio; SBP, systolic blood pressure.
aAdjusted for age, sex, body mass index, smoking, prevalent ischemic heart disease, stroke, baseline diastolic blood pressure, antihypertensive medications, statin
administration, aspirin usage, low-density-lipoprotein cholesterol, high-density-lipoprotein cholesterol, triglycerides, glycosylated hemoglobin, hs-C-reactive protein, and
homocysteine.
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cohort was comparable with the mean carotid IMT at
baseline of CKD participants in the INVADE cohort
(0.81±0.20 vs 0.84±0.21 mm). In contrast to our study,
this study did not assess the relationship between blood
pressure, kidney function, and carotid IMT progression.
Observational studies suggest that a SBP level
o120 mm Hg may be ideal in individuals in the general
population, as this blood pressure level is associated with
a decreased risk of CVD compared with those with a
SBP4120 mm Hg in the general population.4,30 In the CKD
population, higher SBP is associated with an increased risk
of cardiovascular events and the blood pressure level is
progressively lowered in this population.12 However, in
contrast to our findings, other observational studies examin-
ing blood pressure levels in CKD patients have found a
J-shaped relationship with an increased risk of cardiovascular
events with a SBPo120 mm Hg.13,14,31
A recent population-based study of patients with CKD
stages III and IV (mean estimated glomerular filtration rate
51±8.4 ml/min per 1.73 m2) found an increased risk of
stroke with a baseline SBPo120 mm Hg.13 Individuals with
CKD and a SBP levelo120 mm Hg had a two-fold increased
risk of stroke compared with those with CKD and a SBP level
between 120 and 129 mm Hg (hazard ratio 2.51, 95% CI:
1.30–4.87). Subjects without CKD had a linear relationship
between SBP and stroke. Although this patient population
is similar to that ours, other vascular events besides stroke
were not evaluated. Furthermore, the two cohorts that were
pooled in this study seem to have inherent differences as the
increased risk of stroke with lower SBP level was only seen
in CKD patients from one cohort. In our study, individuals
with and without CKD had a linear relationship between
baseline SBP levels and vascular events (including stroke),
with a trend toward a decreased risk of vascular events with a
baseline SBP level o120 mm Hg after adjustment for both
traditional and nontraditional risk factors. Furthermore,
a baseline SBP level X140 mm Hg predicted vascular events
in both CKD and non-CKD patients after multivariate
analysis. Thus, our results suggest that blood pressure should
be managed aggressively in both groups of patients.
Our study has several limitations that should be con-
sidered. First, the definition of kidney disease was based on
Ccr rather than on more precise measures of kidney function,
such as iothalamate clearance. Second, we did not have
information on the cause or duration of kidney disease or on
albuminuria, a known CVD risk factor. Third, CKD status
was categorized only by baseline values and a misclassification
of subjects may have occurred. Fourth, we evaluated only SBP
and antihypertensive medication use at the initiation of the
study and not achieved blood pressure targets; this may not
capture important information that is reflected in changes in
antihypertensive regimens during the 4-year follow-up period.
Finally, the results of this study are most applicable to elderly
patients with stage III CKD, and caution should be exercised
while extrapolating these results to younger patients or
patients with more advanced kidney disease.
Notwithstanding these limitations, our study also has
several strengths, including the large number of patients, the
complete nature of the data set, and the follow-up period of
4 years. In addition, we were able to adjust for multiple
factors that may affect progression of subclinical athero-
sclerosis. Furthermore, all measurements including carotid
IMT and blood pressure were carried out in a standardized
manner and all laboratory measurements were performed in
a central laboratory.
In conclusion, the high prevalence of hypertension in
CKD patients may help explain their increased risk of CV
events and mortality. Thus, it is important to find the ideal
blood pressure target in this high-risk population. Our data
suggest that CKD subjects with higher baseline SBP level
had greater carotid IMT progression and an increased risk
of vascular events. Large randomized trials are required to
confirm the optimal SBP target in CKD patients.
MATERIALS AND METHODS
Study population
The design of the INVADE study, a prospective, population-based
cohort of the elderly, has been described previously.21 Briefly, all
the inhabitants of the community of Ebersberg, Germany, born
before 1946, and members of the health insurance company AOK
(Allgemeine Ortskrankenkasse) were identified in the AOK database
and invited to participate (n¼ 10,325). In the community of
Ebersberg, more than 40% of all inhabitants aged 455 years were
AOK members. A total of 3905 participants followed up the
invitation during the baseline phase from 2001 to 2003, of which
3364 were included in this study. The remaining subjects were
excluded because of incomplete laboratory data (n¼ 365), missing
(n¼ 95) or not analyzable (n¼ 81) carotid IMT. The baseline
investigation was carried out by primary care physicians of the
community of Ebersberg (n¼ 65) and included a standardized
questionnaire, medical history, physical examination, evaluation of
several risk factors, a 12-lead electrocardiogram, and an overnight
fasting venous blood sample for analysis in a central laboratory.
A duplex ultrasonographic examination of the carotid arteries was
performed in all subjects according to a standardized protocol by
eight experienced investigators after training. All data were entered
into a central database after plausibility checks for further
evaluation. After the initial baseline investigation, the primary care
physician assessed the subjects every 3 months. Complete evalua-
tions were scheduled after 4 years of follow-up. The local
institutional review board approved this study, and all participants
provided informed consent before entering the study.
Primary predictor and outcomes
SBP was the main predictor for all analyses. It was measured at
baseline investigation by the primary care providers in a standar-
dized manner on the basis of recommendations made by the
Seventh Report of the Joint National Committee and by the
American Heart Association.12,32 Briefly, blood pressure was
measured in a sitting position after the patient had relaxed for
5 min. Blood pressure was measured twice with an interval of 5 min
on both arms using an auscultatory device. The average value of all
measurements was used, except in the case in which the difference
between both arms was 410 mm Hg. In these cases, higher arm
values were used. If there was a 45 mm Hg difference between the
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first and second readings, two additional readings were obtained, and
then the average of these multiple readings was used. The cuff size was
adjusted according to the arm circumference. All used monitors were
validated, and all technicians were trained by a physician. For our
analysis, SBP was evaluated using four strata: o120, 120–129,
130–139, and X140 mm Hg. We chose to evaluate ranges of SBP as
previous studies have shown that cardiovascular risk increases as SBP
increases.13,14,33 Pulse pressure was also evaluated as another predictor
for all analyses. Again, we chose to evaluate ranges of pulse pressure as
studies have shown increased cardiovascular risk with higher pulse
pressures.34 Thus, pulse pressure was divided into quartiles o47.5,
47.5–55.5, 55.5–66, and 466 mm Hg.
The main outcomes in this analysis were carotid IMT
progression and cardiovascular events. Carotid IMT was measured
through duplex ultrasonography performed by eight experienced
investigators using a standardized protocol. The initial and follow-
up duplex sonography was performed by the same investigator.
Ultrasound data were stored on video or digital audiotapes,
transferred to the neurovascular laboratory of the Department
of Neurology, and were digitalized if necessary. Measurements of
mean common carotid IMT were performed as previously described
in detail using a computer-supported image analysis system
(SigmascanPro 5.0, Systat Software, San Jose, CA, USA).35
Standardized interrogation angles were used, according to recom-
mendations described previously, to enhance the reproducibility of
carotid measures.36 Intra- and inter-observer agreements were
evaluated as follows. Carotid IMT measurements were carried out
in 10 healthy subjects aged 455 years by all 8 duplex investigators
before the study onset. These measurements were repeated three
times over a period of 3 weeks. From these data, intra- and
inter-observer agreements were calculated using k-statistics. The
intra- and inter-observer agreements for measurement of carotid
IMT were 0.93 and 0.83, respectively. The progression of early
carotid atherosclerosis was defined as the difference between the first
and the last (at 4 years of follow-up) carotid IMT measurement and
was normalized as the change in carotid IMT per year.
In this analysis, we used the same cardiovascular end points
specified by the original INVADE study. The end points were the
occurrence of major cardiovascular events defined as a composite of
myocardial infarction, stroke, and vascular death. Once subjects
entered the INVADE study, they were continuously monitored for
major cardiovascular events through linkage of the study database
with the 3-month visit files from the primary care physicians, the
AOK database, and the municipality. If an event was reported,
additional information was obtained through hospital records,
autopsy records, and death certificates. Two physicians (DS and HG)
independently coded all fatal and nonfatal events.
Definition of kidney function
As a number of factors such as age, sex, and weight can influence
serum creatinine levels, kidney function was calculated as Ccr by the
Cockcroft–Gault equation.37,38 The Cockcroft–Gault equation in-
cludes measurements of age, weight, and sex and is standardized for
body surface area as follows:
Ccr (ml/min per 1.73 m2)¼ ((140age) (weight) (0.85 if
female))/((72 serum creatinine) 1.73 m2), where serum creati-
nine is measured in mg/dl, age in years, weight in kilograms, and the
body surface area using the Dubois formula.39 For this analysis,
CKD was defined as a Ccr o60 ml/min per 1.73 m2. The analysis
was again repeated estimating kidney function using the four-
variable MDRD prediction equation.38
Baseline covariates
A computerized questionnaire at baseline was used to obtain
information regarding current health status, medical history,
lifestyle, drug use, and former cardiovascular risk factors. These
patient factors were confirmed and documented by a physician
during the baseline history and physical examination. Risk factors
determined included body mass index (kg/m2), smoking status,
medication usage, arterial hypertension (treatment with antihyper-
tensive medications or documented blood pressure X140 mm Hg
systolic or X90 mm Hg diastolic measured in a standardized
manner,12 diabetes mellitus (treatment with antidiabetic drugs or
overnight fasting serum glucose levels X126 mg/dl), prevalent
ischemic heart disease (documented by previous myocardial
infarction or angina, bypass surgery, or 450% stenosis of X1
major coronary artery), prevalent peripheral vascular disease
(according to the Transatlantic Intersociety Consensus Criteria40),
and prevalent stroke (neurological deficit that persisted 424 h,
evaluated by a neurologist). Myocardial infarction and angina were
diagnosed according to recent recommendations.41,42
Overnight fasting blood samples were collected from each subject
and were transferred on ice to a central laboratory where all analyses
were performed. Serum creatinine was assessed using a kinetic
alkaline picrate (Jaffe) method.43 A high sensitivity assay (N High
Sensitivity CRP, DADE Behring, Eschborn, Germany) was used for
the measurement of serum high sensitivity CRP with a lower
detection level of 0.175 mg/l and a coefficient of variation of 7.6%.
Total homocysteine levels were measured using high-performance
liquid chromatography with fluorescence detection.44,45 Glycosy-
lated hemoglobin (HbA1c) was measured by high-pressure liquid
chromatography separation of hemoglobin fractions with a
reference value of 4.0–6.0% and a coefficient of variation of 1.8%
on a Hi nAuto A1c HA-8140 device (KDK, Kyoto, Japan).
Statistical analysis
All values are given as mean and s.d., or 95% CIs, or as counts and
percentages. We used w2 tests, independent t-tests, Mann–Whitney
U-tests, and the Spearman rank correlation for univariate analysis,
as appropriate. For this analysis, we divided the population into two
groups, that is, subjects with CKD and those without CKD, to test
whether the effect of SBP and pulse pressure is significantly different
for those with and without kidney disease. Analyses were stratified
by kidney function status after statistically significant interactions of
kidney function with SBP and pulse pressure were found. We
evaluated the association across ranges of SBP and pulse pressure
with baseline carotid IMT and carotid IMT progression in both
kidney function groups using multiple linear regression techniques,
and covariate-adjusted mean carotid IMT values were reported.
Hazard ratios were calculated using the Cox proportional hazard
regression model. The proportional hazards assumption was
satisfied. All fully adjusted models were fitted using the same
potential clinically significant predictors of carotid IMT and incident
cardiovascular outcomes, including age, sex, body mass index,
smoking, prevalent ischemic heart disease, stroke, antihypertensive
medications, statin administration, aspirin usage, low-density
lipoprotein-cholesterol, high-density lipoprotein-cholesterol, trigly-
cerides, HbA1c, hs-CRP, and homocysteine. It is noteworthy that
diastolic blood pressure was included as a covariate in all analyses
in which SBP was examined as a predictor, and SBP and diastolic
blood pressure were included as covariates in all analyses in which
pulse pressure was examined as the exposure variable. For analyses
of carotid IMT progression, baseline carotid IMT was additionally
Kidney International (2010) 77, 794–800 799
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included as a continuous covariate. Calculations were performed
using the JMP 7.0 software (SAS, Cary, NC, USA). P-values o0.05
were considered to be statistically significant.
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